Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Recce Pharmaceuticals Ltd. ( (AU:RCE) ) has shared an announcement.
Recce Pharmaceuticals will host a live online investor webinar on 19 March 2026 to update stakeholders on its advancing anti-infective programs. The session, held via Zoom and later available as a recording, aims to broaden investor understanding of the company’s pipeline and strategic direction.
The webinar will feature expert presentations on the company’s registrational Phase 3 trial for diabetic foot infections in Indonesia and its U.S. Department of War burn wound program. Management will also outline progress across the wider anti-infective portfolio and operational highlights, underscoring Recce’s efforts to position itself as a key player in next‑generation anti‑infective therapeutics.
The most recent analyst rating on (AU:RCE) stock is a Sell with a A$0.42 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd. is an Australia-based biotechnology company developing a new class of synthetic anti-infective therapies. Its portfolio spans clinical and pre-clinical programs targeting serious infections, with a particular focus on conditions such as diabetic foot infections and burn wound infections in collaboration with U.S. defense-related initiatives.
Average Trading Volume: 101,616
Technical Sentiment Signal: Sell
Current Market Cap: A$137.4M
Find detailed analytics on RCE stock on TipRanks’ Stock Analysis page.